Table 2.

Clinical characteristics of the participants with HA

TotalHistoric INH ≥ 5 BU/mL Historic INH < 5 BU/mLRecent INH ≥ 5 BU/mLRecent INH < 5 BU/mLCurrent INH ≥ 0.6 BU/mLRecent titer unknown
Total 394 66 58 45 39 28 71 
Black 188 36 31 36 31 16 31 
White 206 30 26 12 40 
Severe HA, Black 162 34 27 34 26 14 27 
Severe HA, White 185 27 22 11 39 
Mild + moderate HA, Black 26 
Mild + moderate HA, White 21 
Haplotype, race        
H1, Black 60 12 10 10 
H2, Black 90 15 15 16 
H3, Black 28 
H4, Black 
H5, Black 
Haplotype unknown, Black 
H1, White 156 21 20 10 30 
H2, White 43 10 
H3, White 
H4, White 
H5, White 
Haplotype unknown, White 
Mutation class, race        
Intron-22 inversion, Black 57 13 13 11 
Intron-1 inversion, Black 
Mutation unknown, Black 26 
Intron-22 inversion, White 87 12 11 11 20 
Intron-1 inversion White 
Mutation unknown White 12 
Age (y) at enrollment, race        
2-3, Black 10 
2-3, White 
4-17, Black 74 10 11 10 11 12 
4-17, White 73 12 12 12 12 15 
≥18, Black 104 23 19 11 17 
≥18, White 128 16 13 23 
TotalHistoric INH ≥ 5 BU/mL Historic INH < 5 BU/mLRecent INH ≥ 5 BU/mLRecent INH < 5 BU/mLCurrent INH ≥ 0.6 BU/mLRecent titer unknown
Total 394 66 58 45 39 28 71 
Black 188 36 31 36 31 16 31 
White 206 30 26 12 40 
Severe HA, Black 162 34 27 34 26 14 27 
Severe HA, White 185 27 22 11 39 
Mild + moderate HA, Black 26 
Mild + moderate HA, White 21 
Haplotype, race        
H1, Black 60 12 10 10 
H2, Black 90 15 15 16 
H3, Black 28 
H4, Black 
H5, Black 
Haplotype unknown, Black 
H1, White 156 21 20 10 30 
H2, White 43 10 
H3, White 
H4, White 
H5, White 
Haplotype unknown, White 
Mutation class, race        
Intron-22 inversion, Black 57 13 13 11 
Intron-1 inversion, Black 
Mutation unknown, Black 26 
Intron-22 inversion, White 87 12 11 11 20 
Intron-1 inversion White 
Mutation unknown White 12 
Age (y) at enrollment, race        
2-3, Black 10 
2-3, White 
4-17, Black 74 10 11 10 11 12 
4-17, White 73 12 12 12 12 15 
≥18, Black 104 23 19 11 17 
≥18, White 128 16 13 23 

INH, inhibitor titer ≥0.6 BU/mL. “Recent” titers include those measured by CNBA assays performed as part of this study. In cases in which plasma volumes were not available to perform a CNBA assay, recent titers are from clinical records of assays performed within 2 years of enrollment in this study. In cases in which the most recent clinical titer was ≥5 BU/mL but the CNBA assay results showed a titer <5 BU/mL, the participant was classified as having a recent inhibitor titer of ≥5 BU/mL. Note that the “current inhibitor” designation refers only to the 28 patients whose plasma samples collected for this study showed titers ≥0.6 CNBU/mL.

or Create an Account

Close Modal
Close Modal